Ignyta, a clinical-stage biotech developing targeted cancer therapeutics, filed on Friday with the SEC to raise up to $40 million in an initial public offering. The San Diego, CA-based company, which was founded in 2011, plans to list on the NASDAQ under the symbol RXDX. Ignyta is currently traded on the OTC market under the same ticker. Leerink Partners is the sole bookrunner on the deal. No pricing terms were disclosed.
